Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.
20 May 2015 | European Liver Patients Association
Hepatitis B stimulates processes that deprive the body’s immune cells of key nutrients that they need to function, finds new UCL-led research funded by the Medical Research Council and Wellcome Trust. The work helps to explain why the immune system cannot control hepatitis B virus infection once it becomes established in the liver, and offers a target for potential curative treatments down the line.
14 May 2015 | University College London press release
A potential cure for hepatitis B virus infections has been found with a promising new treatment proving 100 per cent successful in eliminating the infection in preclinical models. Australian patients are now the first in the world to have access to the potential treatment -- a combination of an antiviral drug and an anti-cancer drug -- which is in phase 1/2a clinical trials.
21 April 2015 | Science Daily
After receiving a clinical hold from the FDA earlier this year, Arrowhead Research Corporation has now been approved by the FDA to begin a multiple-dose phase 2b clinical study of ARC-520 for the treatment of chronic hepatitis B infection, according to a news release from the drug maker.
14 April 2015 | Healio Hepatology
In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration and costs less than $1 per dose to manufacture.
01 April 2015 | Medical Xpress
WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries.
12 March 2015 | World Health Organization
Gilead Sciences Inc. raked in $10 billion last year with its Sovaldi pill for hepatitis C. Many of the people responsible for the drug are now competing to repeat that success for a more common liver disease: hepatitis B.
05 February 2015 | Bloomberg
The Journal of Virus Eradication is a new open-access online and print journal dedicated to the rapidly developing field of virus eradication. It is particularly interested in publishing original research on HIV, hepatitis viruses, HPV, herpes and flu but work on other viruses is also included. The first issue was successfully launched at the HIV and Hepatitis Five Nations Conference in London
on 8 December 2014 and is available now on the Journal website: www.viruseradication.com
23 December 2014 | Mediscript
There is a virus that is 100 times more easily transmitted than the dreaded acquired immunodeficiency syndrome virus, and it is called Hepatitis B Virus (HBV). HBV is a virus that can cause Chronic Hepatitis B, a life threatening liver disease. According to United States Center for Disease Control and Prevention (CDC), up to 25 percent of people with chronic hepatitis B develop serious liver problems such as liver failure, liver cancer and cirrhosis (severe liver scarring), if left untreated.One in 10 Asian Americans has HBV- a rate over 20 times higher than that of the overall U.S. population - two in three of whom are not aware of it.
27 August 2014 | Philippine Star
Lei Chuang trekked almost 1,000 miles over 80 days from Shanghai to Beijing last summer, along riverbanks and highways, to deliver a petition beseeching China’s leaders to cut the prices of hepatitis B drugs. “If drug companies can afford such huge sums for bribing doctors and hospitals, then they should still be profitable if prices are lowered by 50 percent,” said Guangzhou-based Lei, nicknamed the “Hepatitis B Warrior” by Chinese media. “They could use that money to benefit patients instead.”
30 May 2014 | Bloomberg